Skip to the main content.
Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Turn Our Insights Into Your Impact

From early feasibility to commercialization, progress depends on the right decisions at the right time. Get confident in your next step with blogs, case studies, and expert insights that cut through complexity and move development forward.

 

6 min read

Four Pillars to Assess the Clinical Adoption Case for Artificial Intelligence

Four Pillars to Assess the Clinical Adoption Case for Artificial Intelligence
Four Pillars to Assess the Clinical Adoption Case for Artificial Intelligence
12:12

By Rosel Van Den Berg with Annika Hay and Martha Hodgson contributing.

A healthcare AI (Artificial Intelligence) solution can be technically excellent and still fail to gain traction in clinical practice.

Technical feasibility alone does not guarantee success. Developers must also establish desirability, whether the solution addresses a meaningful clinical need and fits how care is delivered, and viability, whether it can create sustainable value for the stakeholders involved. Even a highly accurate algorithm may struggle to gain adoption if clinicians see limited value in its outputs or face barriers to incorporating it into practice.

Before committing significant resources, whether through internal development budgets or external funding, developers should test the clinical adoption case: the evidence and assumptions that explain why an AI-enabled product is likely, or unlikely, to be incorporated into clinical practice. Doing so early can reveal adoption risks, uncover product opportunities, and guide decisions about where to invest and what to prioritize.

Before investing in healthcare AI, test the clinical adoption case

Rather than treating clinical adoption as a consideration for later-stage commercialization, developers should assess it during early needs identification and strategic planning, when there is still time to challenge assumptions and shape the product's direction.

Drawing on our research with healthcare AI innovators, we have identified four pillars for assessing the clinical adoption case: clinical value, trust and explainability, workflow fit, and ecosystem and incentives.

Each pillar includes two practical assessment questions to help developers test assumptions, identify evidence gaps, and prioritize what to investigate next. Together, they provide a framework for making more informed product and investment decisions.

clinical-value-icon

1. Clinical value - Is the benefit strong enough to change current practice?

Just because AI can address a problem does not mean it will create enough value to change clinical practice. In our work with AI-enabled clinical solutions, we have seen that technical capabilities do not automatically translate into meaningful clinical benefits. For example, an algorithm may generate sophisticated quantitative information, but its value remains limited if clinicians cannot interpret it or meaningfully incorporate it into their decisions.

The relevant comparison is not AI versus nothing, but AI versus how the problem is managed today. The improvement must move the needle enough to justify changing established clinical practice.

To assess this potential, developers should validate their assumptions through contextual inquiry and task analysis, focusing on two key questions:

  1. What significant problem in current practice needs to be solved? Understand existing workflows, workarounds, and sources of burden or risk to identify where meaningful opportunities for improvement exist.
  2. What measurable improvement would justify changing current practice? Look beyond AI features to outcomes such as time saved, fewer missed findings, greater consistency, improved patient safety, faster decisions, or enabling clinicians to apply their expertise more effectively.

trust-explainability-icon

2. Trust and explainability - Will clinicians know when to rely on it?

Trust is frequently cited as a prerequisite for AI adoption, and for good reason. In healthcare, even highly accurate algorithms can pose significant clinical risks when errors are difficult to detect or have serious consequences for patient care.

However, maximizing trust should not be the main goal. Healthcare AI requires appropriate trust: clinicians need sufficient confidence to rely on AI outputs while understanding their limitations and recognizing where their own clinical judgment remains essential.

Our research with clinicians has highlighted that overall algorithm accuracy alone may not be enough to establish confidence. Consider an AI-generated imaging report: even a highly accurate algorithm may be difficult to rely on if it has not been validated for the relevant patient population, its findings are presented without sufficient clinical context, or clinicians cannot determine how the results should inform their decisions. Appropriate trust requires clinicians to understand when AI outputs are reliable, how to interpret them, and what to do with the information.

The key is not simply whether clinicians trust AI, but whether they know when and how to rely on it.

To assess appropriate trust, developers should engage clinicians early to understand what they need to evaluate and interpret AI outputs, and how the AI should support their clinical judgment. Two questions can guide this assessment:

  1. What evidence and information do clinicians need to rely on AI outputs appropriately? Assess expectations for clinical validation, including comparisons with expert assessments and testing in representative clinical settings. Explore what clinicians need to know about the algorithm's performance and limitations, and how findings and relevant clinical parameters should be presented to support interpretation.
  2. How should the AI support clinical judgment and decision-making? Establish whether the AI is informing, recommending, or making decisions, how clinicians can interrogate or challenge its outputs, and who retains responsibility when the clinician and algorithm disagree.

workflow-fit-icon

3. Workflow fit - Can the product survive real clinical practice?

The algorithm is only one part of the product clinicians ultimately experience. Even a technically strong AI capability can struggle to gain adoption if it adds steps, requires clinicians to leave existing systems, duplicates activities, or delivers information at the wrong point in the workflow. For example, requiring clinicians to manually copy patient information from an electronic health record (EHR) into a separate AI application, and then transfer the results back, can introduce additional work and opportunities for error.

Our research has shown that the clinical value of AI depends not only on the algorithm's performance, but also on how its outputs are presented, interpreted, and incorporated into clinical workflows. Understanding real-world workflows can therefore do more than improve usability. It can reshape the product concept itself, revealing where the AI should be integrated, who should interact with it, and what experience is needed to deliver value in practice.

To assess workflow fit, developers should observe real clinical workflows and test how the AI solution would be used in practice. Workflow research should help developers understand the following:

  1. How can the AI integrate into existing clinical workflows with minimal disruption? Assess whether it can use existing data formats and systems, where its outputs should appear, and whether it introduces additional steps, interfaces, or administrative burden.
  2. What experience is needed for clinicians to use the AI effectively? Identify who operates the product and who uses its outputs, how clinicians need to interact with the results, and what learning curve or training is required to incorporate the AI into everyday practice.

ecosystem-incentives-icon

4. Ecosystem and incentives - Does adoption support the commercial case?

Clinical adoption does not happen between an algorithm and a single clinician. Healthcare AI operates within an ecosystem of users, data, systems, decision-makers, beneficiaries, and buyers.

Consider an AI-generated MRI report: a technologist acquires the images, an AI algorithm analyzes them, a radiologist reviews the results, and a specialist uses the information to inform clinical decisions. While each stakeholder plays a different role, the value, effort, and responsibility associated with the solution may be distributed unevenly. The organization funding the solution may have yet another perspective on its value.

Beyond stakeholder alignment, adoption also depends on the broader technical and organizational environment. Our research has highlighted the importance of reliable data, interoperability with existing systems, patient data privacy and security, and the IT resources needed to deploy and maintain AI solutions across clinical settings.

A strong clinical value proposition does not automatically translate into a viable adoption and commercial model. Developers need to understand both the practical requirements for implementation and the incentives that will sustain use over time.

Two areas deserve particular attention:

  1. Can the healthcare organization support the AI solution in practice? Assess how data is generated, transferred, and protected; whether the product can integrate with existing systems such as EHRs; what applicable privacy, security, and regulatory requirements must be addressed; and what resources are needed for implementation and ongoing maintenance.
  2. Do stakeholder incentives support sustained adoption? Identify who operates the solution, who benefits from its outputs, who takes on additional work or responsibility, and who pays. Determine whether the benefits are compelling enough for each stakeholder whose participation is essential.

Build the adoption case as the product matures

The clinical adoption case cannot, and should not, be answered in a single study.

Early research can establish the unmet need, current context of use, and value proposition. Concept and prototype research can explore workflow fit, usability, and appropriate reliance. Later work can test evidence expectations, implementation barriers, and ultimately real-world use. Each stage should de-risk the innovation pathway by resolving the uncertainties that matter most before the next expensive decision.

This is where ethnographic research can be particularly valuable. Interviews can tell you what clinicians say; observing real workflows can reveal the workarounds, handoffs, competing incentives, and contextual factors that shape what they actually do.

For healthcare AI developers, adoption research should therefore not be something used to make a finished product more acceptable. Done early, it becomes an input to product, commercial, and investment strategy, helping to determine which capabilities to prioritize, where to differentiate, what partnerships may be needed, and where further investment will create the most value.

These insights can inform different decisions depending on the organization. For established healthcare companies, they provide a stronger basis for continuing, repositioning, or redirecting an investment. For startups, they help identify which uncertainties to resolve next, avoiding the costly mistake of building the wrong things. Veranex’s Research & Strategy team applies early adoption research to turn real-world clinical insight into evidence that informs better product and investment decisions.

Before asking “Can we build it?”, make sure you can also answer: “Should we, and what do we need to learn before we invest further?”

About the author: Rosel Van Den Berg is senior principal design researcher.

About Research & Strategy at Veranex

Research & Strategy is where Veranex makes sure you are solving the right problem before you invest in solving it well. Grounded in ethnographic research, workflow mapping, and market-access intelligence, this team defines the opportunity space and value story that will guide Design, Engineering, Human Factors, and commercial decisions. Insights do not sit in slideware: they flow straight into Product Design & Engineering, Human Factors, and Commercial Strategy & Market Access, shaping design inputs, claims, and evidence needs. Because the same iCRO team carries that insight into Preclinical, Clinical Research, and Regulatory work, you avoid reinvention, late pivots, and wasted capital. 

Design & Development Callout